Publication date: December 2017
Source:Advances in Biological Regulation, Volume 66
Author(s): Takao Fujisawa
Apoptosis signal-regulating kinase 1 (ASK1) is a member of the stress-activated mitogen-activated protein kinase kinase kinase (MAP3K) family. ASK1 is an attractive drug target, owing to its essential role in a wide variety of human diseases including neurodegenerative disorders, inflammatory diseases and cancer. Recent studies have suggested that pharmacological manipulations using small molecule ASK1 inhibitors may be beneficial in experimental human disease models. In this review, we highlight the current understanding of ASK1 inhibitors as a potential therapy for human diseases.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kBg8sh
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Kenaf is a multipurpose crop, but a lack of genetic information hinders genetic and molecular research. In this study, we aimed t...
-
As demonstrated by the market reactions to downgrades of various sovereign credit ratings in 2011, the credit rating agencies occupy an impo...
-
Spindle cell/pleomorphic lipoma is an uncommonly encountered benign neoplasm that is usually found in the subcutaneous tissues. Rare cases r...
-
Lichtenstein intervention is currently the classic model of the regulated treatment of inguinal hernias by direct local approach. This “tens...
-
Publication date: Available online 10 February 2017 Source: International Journal of Oral and Maxillofacial Surgery Author(s): S. Sugiyama...
-
ORIGINAL ARTICLES Cyclooxygenase-2 and estrogen receptor-β as possible therapeutic targets in desmoid tumors p. 47 Rasha A Khairy DOI :10....
-
New magnetic resonance (MR) molecular imaging techniques offer the potential for non-invasive, simultaneous quantification of metabolic and ...
-
The parotid gland harbors 85% of all salivary gland neoplasms. Though the majority of tumors are benign, complete surgical resection remains...
-
Facial Nerve Clinic to Provide Comprehensive Personalized Care Newswise (press release) The program will treat patients with facial n...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου